HomeInsightsStock Comparison

Dr Reddys Laboratories Ltd vs Sanofi India Ltd Stock Comparison

Dr Reddys Laboratories Ltd vs Sanofi India Ltd Stock Comparison

Last Updated on: May 07, 2025

Key Highlights

  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1153 as of 07 May 10:21.
  • The p/e ratio of Dr Reddys Laboratories Ltd changed from 25.6 to 18.4 over 5 quarters. This represents a CAGR of -23.22% The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 7 quarters. This represents a CAGR of -100.00% .
  • The market cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore to ₹ 102679 crore over 5 quarters. This represents a CAGR of 72.88% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% .
  • The revenue of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 8535 crore as compare to the Sep '24 revenue of ₹ 8351 crore. This represent the growth of 2.2% The revenue of Sanofi India Ltd for the Dec '24 is ₹ 526.3 crore as compare to the Sep '24 revenue of ₹ 503.3 crore. This represent the growth of 4.57%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 2427 crore as compare to the Sep '24 ebitda of ₹ 2390 crore. This represent the growth of 1.56% The ebitda of Sanofi India Ltd for the Dec '24 is ₹ 122 crore as compare to the Sep '24 ebitda of ₹ 136.5 crore. This represent the decline of -10.62%.
  • The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1404 crore over 7 quarters. This represents a CAGR of -0.03% The net profit of Sanofi India Ltd changed from ₹ 190.4 crore to ₹ 82.2 crore over 7 quarters. This represents a CAGR of -38.12% .
  • The dividend payout of Dr Reddys Laboratories Ltd changed from 14.14 % to 15.37 % over 5 quarters. This represents a CAGR of 6.90% The dividend payout of Sanofi India Ltd changed from 175.77 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Sanofi India Ltd

  • Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956.
  • The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
  • The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
  • The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
  • It has its own manufacturing facility at Goa.

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys announces cessation of subsidiary in Louisiana

Dr. Reddy's Laboratories Inc., USA, a wholly owned subsidiary of the Company, has successf...

Read more

24 Mar 2025 13:48

News

Dr Reddys Laboratories to conduct board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 9 M...

Read more

22 Mar 2025 11:01

News

Dr. Reddy's recalls Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US

Dr. Reddy's Laboratories is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75%...

Read more

13 Mar 2025 18:46

News

Dr Reddys Laboratories allots 11,250 equity shares under ESOS

Dr Reddys Laboratories has allotted 11,250 equity shares under ESOS on 06 March 2025. Powe...

Read more

06 Mar 2025 19:16

News

Dr Reddy's Lab gets EIR from USFDA for Hyderabad facility

The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and confirmed ...

Read more

27 Feb 2025 09:57

News

Dr Reddys Laboratories allots 20,155 equity shares under ESOS

Dr Reddys Laboratories has allotted 20,155 equity shares of Re.1/- each of the Company, fu...

Read more

14 Feb 2025 18:24

Sanofi India Ltd News Hub

News

Sanofi India MD Rodolfo Hrosz resigns

The board of directors accepted Hrosz's resignation during a meeting held on 9 April and e...

Read more

11 Apr 2025 11:01

News

Sanofi India to convene AGM

Sanofi India announced that the 69th Annual General Meeting(AGM) of the company will be he...

Read more

19 Mar 2025 12:01

News

Board of Sanofi India recommends final dividend

Sanofi India announced that the Board of Directors of the Company at its meeting held on 2...

Read more

28 Feb 2025 09:13

News

Board of Schaeffler India recommends Final Dividend

Schaeffler India announced that the Board of Directors of the Company at its meeting held ...

Read more

27 Feb 2025 17:28

News

Sanofi India to conduct board meeting

Sanofi India will hold a meeting of the Board of Directors of the Company on 27 February 2...

Read more

14 Feb 2025 09:41

News

Sanofi India to discuss results

Sanofi India will hold a meeting of the Board of Directors of the Company on 7 November 20...

Read more

18 Oct 2024 10:45

SWOT Analysis Of Sanofi India Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Sanofi India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dr Reddys Laboratories Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Sanofi India Ltd?

Market cap of Dr Reddys Laboratories Ltd is 96,788 Cr while Market cap of Sanofi India Ltd is 13,426 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Sanofi India Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Sanofi India Ltd?

As of May 7, 2025, the Dr Reddys Laboratories Ltd stock price is INR ₹1159.9. On the other hand, Sanofi India Ltd stock price is INR ₹5829.95.

How do dividend payouts of Dr Reddys Laboratories Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions